Pharmaceutical News

RSS

Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care

A US electronic health record study found that adults with obesity who started semaglutide or tirzepatide had lower recorded hazards of anxiety and depression than matched patients using naltrexone-bupropion. However, among adults without type 2 diabetes, tirzepatide was linked to higher recorded hazards of anxiety and insomnia than semaglutide, underscoring the need for cautious monitoring.

1 Jul 2026

Melatonin may safely reduce chronic musculoskeletal pain, study finds

A sleep supplement widely used to treat insomnia could help reduce reliance on some of the most common and potentially harmful pain medications, new research from the University of Sydney suggests.

30 Jun 2026

Many pharmaceutical active ingredients can switch to PFAS-free alternatives

Certain medicines contain per- and polyfluorinated alkyl compounds, known as PFAS, which are causing increasing environmental harm due to their long-lasting effects.

30 Jun 2026

New Alzheimer drug lecanemab brings modest benefits and high risks

Canada recently approved lecanemab to treat early Alzheimer disease, but the clinical benefits are modest, it carries a risk of serious adverse effects, and treatment is complex.

29 Jun 2026

Scientists discover 70 existing drugs that block deadly hantavirus infections

Researchers screened over 5,000 compounds and successfully pinpointed 70 existing drugs, including unexpected beta-lactam antibiotics, that effectively suppress Puumala orthohantavirus infection in human cells. This milestone drug-repurposing study provides an immediate, fast-tracked pipeline for developing the first approved treatments against life-threatening hantavirus diseases.

28 Jun 2026

Nasal viruses may drive allergic rhinitis, and ribavirin shows early promise as a targeted spray treatment

Nasal commensal viruses may worsen allergic rhinitis by activating type I IFN-linked neutrophils and NET formation. Ribavirin reduced nasal viral abundance and improved symptoms in mice and in a small phase 2 trial.

28 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

US study shows updated COVID vaccines cut hospitalization odds by 55%

The 2025-2026 COVID-19 vaccines were associated with 50% estimated effectiveness against COVID-19-associated emergency department and urgent care encounters among immunocompetent US adults. They were also linked to an estimated 55% effectiveness against COVID-19-associated hospitalization, providing added protection beyond existing immunity from prior infection or vaccination.

24 Jun 2026

Review outlines key strategies to overcome antibody drug conjugate resistance

The first Antibody-drug conjugate (ADC) was approved overa quarter-century ago, and today more than 20 have reached the clinic.

24 Jun 2026

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow.

From FairJourney Biologics S.A. 24 Jun 2026

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

Statins may trigger muscle side effects by activating inflammatory danger signals

An experimental study in Science Advances shows that statins, primarily fluvastatin in these experiments, may promote low-level muscle myopathy by reducing isoprenoid-dependent protein prenylation rather than by cholesterol lowering. In primed muscle cells and mouse models, impaired YAP signaling, reduced glycolysis, NLRP3/caspase-1 activation, and nuclear FOXO accumulation increased atrogin-1, reduced protein synthesis, and weakened muscle function.

22 Jun 2026

GLP-1 medications may lower risk of multiple substance use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

21 Jun 2026

Heart failure treatments protect heart function during cancer therapy

The cardioprotective effects of heart failure treatments in patients with cancer were demonstrated today in a presentation at ESC Cardio-Oncology 2026, the annual conference of the European Society of Cardiology's Council of Cardio-Oncology.

19 Jun 2026

Computer models could design more effective probiotic supplements

Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes' connections to their marketed use, new University of Virginia School of Medicine research reveals.

18 Jun 2026

Weight-loss medications lessen the risk of violent criminal behavior

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain's reward and stress systems.

17 Jun 2026

Oral contraceptive pills may increase binge eating in some women

A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives - but not in all women.

17 Jun 2026

GLP-1 medications may reduce violent behavior in adults

The use of GLP-1 medications commonly prescribed for weight loss or managing diabetes may have effects that extend beyond metabolic health, including on behaviors linked to violence, according to Rutgers researchers.

17 Jun 2026